Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306

被引：0
|
作者：
Pietrantonio, F. [1 ]
Garassino, M. C. [1 ]
Torri, V. [2 ]
de Braud, F. [1 ]
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Med Oncol Unit 1, Milan, Italy
[2] Ist Ric Farmacol Mario Negri, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷 / 10期
关键词：
FLUOROURACIL; LEUCOVORIN; SURVIVAL;
D O I：
10.1093/annonc/mds332
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2771 / 2772
页数：2
相关论文
共 50 条
  • [11] FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
    Heinemann, Volker
    von Weikersthal, Ludwig Fischer
    Decker, Thomas
    Kiani, Alexander
    Vehling-Kaiser, Ursula
    Al-Batran, Salah-Eddin
    Heintges, Tobias
    Lerchenmueller, Christian
    Kahl, Christoph
    Seipelt, Gernot
    Kullmann, Frank
    Stauch, Martina
    Scheithauer, Werner
    Hielscher, Joerg
    Scholz, Michael
    Mueller, Sebastian
    Link, Hartmut
    Niederle, Norbert
    Rost, Andreas
    Hoeffkes, Heinz-Gert
    Moehler, Markus
    Lindig, Reinhard U.
    Modest, Dominik P.
    Rossius, Lisa
    Kirchner, Thomas
    Jung, Andreas
    Stintzing, Sebastian
    LANCET ONCOLOGY, 2014, 15 (10): : 1065 - 1075
  • [12] BRAF mutant and RAS mutant patients treated with FOLFIRI plus Bevacizumab or FOLFIRI plus Cetuximab. Role of ETS and molecular markers in FIRE-3 (AIO KRK-0306)
    Stintzing, S.
    von Weikersthal, L. Fischer
    Decker, T.
    Kiani, A.
    Vehling-Kaiser, U.
    Al-Batran, S. -E.
    Heintges, T.
    Lerchenmueller, C.
    Kahl, C.
    Seipelt, G.
    Kullmann, F.
    Stauch, M.
    Hielscher, J.
    Lerch, M.
    Scheithauer, W.
    Jagenburg, A.
    Held, S.
    Modest, D.
    Jung, A.
    Kirchner, T.
    Heinemann, V.
    ANNALS OF ONCOLOGY, 2016, 27 : 112 - 112
  • [13] Per protocol analysis and final OS update of the FIRE-3 (AIO KRK-0306) study comparing FOLFIRI plus cetuximab vs. FOLFIRI plus bevacizumab.
    Stintzing, Sebastian
    Miller-Phillips, Lisa
    von Weikersthal, Ludwig Fischer
    Decker, Thomas
    Kiani, Alexander
    Vehling-Kaiser, Ursula
    Al-Batran, Salah-Eddin
    Lerchenmuller, Christian A.
    Kahl, Christoph
    Seipelt, Gernot
    Kullmann, Frank
    Moehler, Markus H.
    Scheithauer, Werner
    Held, Swantje
    Modest, Dominik Paul
    Jung, Andreas
    Kirchner, Thomas
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [14] Influence of adjuvant pretreatment on outcome of FIRE-3 (AIO KRK-0306): A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients
    Stintzing, Sebastian
    Modest, Dominik Paul
    von Weikersthal, Ludwig Fischer
    Decker, Thomas
    Kiani, Alexander
    Vehling-Kaiser, Ursula
    Al-Batran, Salah-Eddin
    Heintges, Tobias
    Lerchenmuller, Christian A.
    Kahl, Christoph
    Seipelt, Gernot
    Kullmann, Frank
    Stauch, Martina
    Scheithauer, Werner
    Held, Swantje
    Giessen, Clemens Albrecht
    Moehler, Markus Hermann
    Jung, Andreas
    Kirchner, Thomas
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [15] Cost-effectiveness of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in the first-line (1L) treatment of RAS wild-type (wt) metastatic colorectal cancer (mCRC) in Germany: Data from the FIRE-3 (AIO KRK-0306) study
    Stintzing, Sebastian
    van Oostrum, Ilse
    Pescott, Chris
    Steinbach-Buechert, Alma Katharina
    Heeg, Bart
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [16] Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment
    Huang, Ching-Wen
    Yeh, Yung-Sung
    Ma, Cheng-Jen
    Tsai, Hsiang-Lin
    Chen, Chao-Wen
    Huang, Ming-Yii
    Lu, Chien-Yu
    Wu, Jeng-Yih
    Wang, Jaw Yuan
    CHEMOTHERAPY, 2017, 62 (01) : 80 - 84
  • [17] Time-course evaluation of survival and treatment in FIRE-3 (AIO KRK0306, first-line therapy of KRAS wild-type metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab).
    Modest, Dominik Paul
    Stintzing, Sebastian
    von Weikersthal, Ludwig Fischer
    Sobrero, Alberto F.
    Decker, Thomas
    Kiani, Alexander
    Vehling-Kaiser, Ursula
    Al-Batran, Salah-Eddin
    Heintges, Tobias
    Seipelt, Gernot
    Lerchenmuller, Christian A.
    Kahl, Christoph
    Kullmann, Frank
    Stauch, Martina
    Scheithauer, Werner
    Held, Swantje
    Moehler, Markus H.
    Jung, Andreas
    Kirchner, Thomas
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [18] Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer
    Modest, Dominik P.
    Stintzing, Sebastian
    von Weikersthal, Ludwig Fischer
    Decker, Thomas
    Kiani, Alexander
    Vehling-Kaiser, Ursula
    Al-Batran, Salah-Eddin
    Heintges, Tobias
    Lerchenmueller, Christian
    Kahl, Christoph
    Seipelt, Gernot
    Kullmann, Frank
    Stauch, Martina
    Scheithauer, Werner
    Held, Svantje
    Moehler, Markus
    Jung, Andreas
    Kirchner, Thomas
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (32) : 3718 - +
  • [19] A COMPARISON OF XELIRI PLUS BEVACIZUMAB WITH FOLFIRI PLUS BEVACIZUMAB AS FIRST-LINE SETTING IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Ahmet, Bilici
    Uygun, Kazim
    Kaya, Serap
    Ustaalioglu, Bala Basak Oven
    Yildiz, Ramazan
    Temiz, Suleyman
    Seker, Mesut
    Aksu, Gorkem
    Cabuk, Devrim
    Gumus, Mahmut
    ANNALS OF ONCOLOGY, 2012, 23 : 98 - 99
  • [20] A COST AND OUTCOMES ANALYSIS OF BEVACIZUMAB PLUS FOLFIRI VERSUS CETUXIMAB PLUS FOLFIRI FOR THE TREATMENT OF FIRST-LINE METASTATIC COLORRECTAL CANCER PATIENTS FROM THE BRAZILIAN PRIVATE PAYER PERSPECTIVE
    Caponero, R.
    Santos, E. A., V
    Buschinelli, C. T.
    Ferracini, M.
    Ngoh, C. A.
    VALUE IN HEALTH, 2011, 14 (07) : A446 - A446
12345